790 Current Reporting Trends, Practices, and Resource Utilization in Penile Cancer: A Survey among Genitourinary Pathologists
Recommended Citation
Dhillon J, Lobo A, Akgul M, Acosta A, Chumbalkar V, Vosoughi A, Xu H, Al-Ahmadie H, Al-Obaidy K, Amin M, Aron M, Arora S, Ayyanar P, Bakshi N, Balzer B, Bardia A, Baweja P, Chakrabarti I, Cheng L, Cima L, Colecchia M, Collins K, Compérat E, Das D, Dixit M, Downes M, Elhence P, Epstein J, Galea L, Gandhi J. 790 Current Reporting Trends, Practices, and Resource Utilization in Penile Cancer: A Survey among Genitourinary Pathologists. Lab Invest 2025; 105(3).
Document Type
Conference Proceeding
Publication Date
3-24-2025
Publication Title
Lab Invest
Keywords
programmed death 1 ligand 1, protein p53, toothpaste, adult, condyloma acuminatum, conference abstract, diagnosis, human, immunofluorescence, immunohistochemistry, major clinical study, microscopy, middle aged, pathologist, penile intraepithelial neoplasia, penis, penis amputation, penis cancer, penis carcinoma, practice guideline
Abstract
Disclosures: Jasreman Dhillon: None; Anandi Lobo: None; Mahmut Akgul: None; Andres Acosta: None; Vaibhav Chumbalkar: None; Aram Vosoughi: None; Hongzhi Xu: None; Hikmat Al-Ahmadie: None; Khaleel Al-Obaidy: None; Mahul Amin: None; Manju Aron: None; Samriti Arora: None; Pavithra Ayyanar: None; Neha Bakshi: None; Bonnie Balzer: None; Anand Bardia: None; Pankaj Baweja: None; Indranil Chakrabarti: None; Liang Cheng: None; Luca Cima: None; Maurizio Colecchia: None; Katrina Collins: None; Eva Compérat: None; Debasmita Das: None; Mallika Dixit: None; Michelle Downes: None; Poonam Elhence: None; Jonathan Epstein: None; Laurence Galea: None; Jatin Gandhi: None; Giovanna Giannico: None; Jennifer Gordetsky: None; Gargy Gupta: None; Noopur Gupta: None; Aiman Haider: None; Donna Hansel: None; Arndt Hartmann: None; Colan Ho-Yen: None; Kenneth Iczkowski: None; Ekta Jain: None; Raajul Jain: None; Shilpy Jha: None; Chia-Sui (Sunny) Kao: None; Seema Kaushal: None; Geert van Leenders: None; Kamalesh lenka: None; Jose Lopez: None; Antonio Lopez-Beltran: None; Daniel Luthringer: None; Fiona Maclean: None; Cristina Magi-Galluzzi: None; Vipra Malik: None; Claudia Manini: None; Guido Martignoni: None; Bhavana Mehta: None; Santosh Menon: None; Sunayana Misra: None; Subhashis Mohanty: None; Rodolfo Montironi: None; Sunanda Nayak: None; Jane Nguyen: None; Chara Ntala: None; Pedro Oliveira: None; Adeboye Osunkoya: None; Sachin Patil: None; Maria Picken: None; Dr Prachi: None; Dinesh Pradhan: None; Susan Prendeville: None; Francisco Queipo: None; Gabriela Quiroga-Garza: None; B Vishal Rao: None; Priya Rao: None; Maria Rosaria Raspollini: None; Shruti Sabnis: None; Sankalp Sancheti: None; Diego F Sanchez: None; Judy Sarungbam: None; Rahul Satarkar: None; Swati Satturwar: None; Nuzhat Khatoon Sayyed: None; Rajal Shah: None; Indu Sharma: None; Neha Sharma: None; Shivani Sharma: None; Deepika Sirohi: None; Parul Sobti: None; Shailesh Soni: None; Saraswathy Sreeram: None; Sandhya Sundaram: None; Pheroze Tamboli: None; Nadeem Tanveer: None; Satish Tickoo: None; Ankit Tiwari: None; Reena Tomar: None; Maria Tretiakova: None; Kiril Trpkov: None; Toyonori Tsuzuki: None; Joshua Warrick: None; Ming Zhou: None; Ankur Sangoi: None; Sean Williamson: None; Sambit Mohanty: None Background: Efforts have been made to standardize the reporting and terminology of penile squamous lesions. This applies to grading, utilization, and interpretation of immunohistochemical stains (IHCs) and testing for HPV. Design: To understand the current trends, practices and resource utilization we conducted an online survey asking 30 questions related to practice. Results: Survey was sent to 143 uropathologists world-wide of which 117 (82%) responded. The survey was fairly distributed in terms years of experience. Responses were received from across the world (Figure 1). More than 50% respondents see >20 cases/year. Only 22% of pathologists submit the entire partial penectomies for microscopic examination. 50% of pathologists make a diagnosis of condyloma acuminatum (CA) with dysplasia whereas 33% never make this diagnosis. Penile intraepithelial neoplasia (PeIN) terminology is used by majority (83%). PeIN is usually subtyped by majority (85%) and never by 11%. No consensus was reached for grading HPV-associated penile carcinoma (PC) although 63% would grade basaloid type as poorly differentiated (PD). Some senior pathologists do not grade HPV-associated PC. No consensus was reached on the minimum % of PD foci required in a well to moderately differentiated PC to grade it as PD (Figure 1). About 25% pathologists either do not or rarely use IHCs to diagnose or to subclassify PeIN. HPV testing in PCa is not routinely done by all (Figure 2). P16 IHC is the most common method used to test for HPV. HPV RNA ISH is done by 37%. 63% agreed that HPV-associated PC has better prognosis than HPV-independent. PDL-1 testing is done only when requested by clinicians and ≥1 CPS is used by 51% to call it positive and 5% report the value without interpreting it further. 54% agreed to subclassify PD 1 as low positive (1-19) and high positive (≥20). There was no consensus on cut off criteria to report p53 IHC positive (Figure 2). [Formula presented] [Formula presented] Conclusions: The survey has consensus and differences as follows: 1. PeIN terminology is used by most uropathologists. 2. p16 IHC is the most common method used to subtype PC as HPV-associated. 3. Need criteria for dysplasia in CA. 4. Need guidelines for a uniform grading system for subtypes of HPV-associated PC. 5. Need guidelines on minimum % of PD foci required in a well to moderately differentiated PC to grade it as PD. 6. Need criteria for reporting p53 IHC positive in PC. 7. There is limited experience among uropathologists with PDL-1 reporting.
Volume
105
Issue
3
